New Frontier for ETFs: Space Economy, Prediction Markets
Original Report
On "Bloomberg ETF IQ", Cinthia Murphy, investment strategist at TMX VettaFi, joins Scarlet Fu and Eric Balchunas to discuss "UFO" ETFs, the space economy and prediction markets. (Source: Bloomberg)
Glass House Analysis
This story reflects the interconnected nature of modern economic systems, where developments in one sector inevitably affect others. Understanding these connections is essential for grasping how policy decisions and market movements translate into real-world outcomes for families, workers, and communities. The economy is not an abstract system of numbers—it's the sum total of decisions about who works, who prospers, and who struggles.
The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.
Enjoyed this analysis?
Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.
No spam. Unsubscribe anytime.
More Stories
Tesla sues California DMV to reverse ruling that company engaged in false advertising on FSD
California's DMV previously ruled that Tesla falsely promoted its cars' self-driving capabilities.
Why software stocks lost more than $200 billion in market cap today
For investors to wade back into the software sector, they “want and need to see the stocks stop trading down on new AI headlines,” one analyst says.
Dow has its worst day in a month as Trump looks to impose replacement tariffs
President Donald Trump opened up a new round of verbal attacks against the Supreme Court on Monday, just days after the high court struck down his sweeping tariff program — creating an uneasy...
Novo Nordisk’s stock slips to 4-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product.